{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/","result":{"pageContext":{"chapter":{"id":"3e6af82a-f8f1-5d90-a988-05136fa101f3","slug":"statins","fullItemName":"Statins","depth":2,"htmlHeader":"<!-- begin field 5943d3de-78eb-49c8-9cad-ad0b40e73951 --><h2>Statins</h2><!-- end field 5943d3de-78eb-49c8-9cad-ad0b40e73951 -->","summary":"","htmlStringContent":"<!-- begin item b3f811df-d687-4ecd-a729-a768f0e6ab2e --><!-- end item b3f811df-d687-4ecd-a729-a768f0e6ab2e -->","topic":{"id":"5303951d-71d9-506d-84ec-cbdd7ff3b93e","topicId":"dc4f1ad8-1fac-4248-9071-a622ca58dd2c","topicName":"Lipid modification - CVD prevention","slug":"lipid-modification-cvd-prevention","lastRevised":"Last revised in October 2020","chapters":[{"id":"7834a360-a716-55db-beef-e74397381f6b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4149ed5c-ad54-5793-8860-4b2f82d94427","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"184e9f02-cec5-5813-a428-f3b70683deda","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0fd087eb-ba58-59e6-b641-2161dd021687","slug":"changes","fullItemName":"Changes"},{"id":"6e535866-055b-5f94-8d43-67cc6c3262a6","slug":"update","fullItemName":"Update"}]},{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3de1ddbe-7a0f-5384-9939-9a56d2251dfc","slug":"goals","fullItemName":"Goals"},{"id":"1a8df6be-f747-5d74-81cf-54d938d5944b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80c40530-2e39-55a1-910d-b5226d83d67a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e9906a94-72bf-5a9e-8e05-bb7b6841fec3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"507f0f33-704f-5b79-813e-0ba2a367617e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c55b24f4-39a4-5919-8e05-5afc7b1ae5c6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f02326a5-5f6d-5026-9c8c-745fd760df23","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f4e4cb23-7f1d-5543-a7a5-9316a25c589b","slug":"lipids-cardiovascular-health","fullItemName":"Lipids and cardiovascular health"}]},{"id":"5123c607-afa6-5c07-a939-547efe27b94c","fullItemName":"Management","slug":"management","subChapters":[{"id":"ec817edb-2375-548c-beb5-8afb1596d294","slug":"lipid-therapy-primary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - primary prevention of CVD"},{"id":"4cd90098-cba6-5b78-994c-9fc173b4fb3f","slug":"lipid-therapy-secondary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - secondary prevention of CVD"}]},{"id":"35a2dc51-a5b3-56bd-9a02-c420e08c1d0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3e6af82a-f8f1-5d90-a988-05136fa101f3","slug":"statins","fullItemName":"Statins"}]},{"id":"238b503e-9352-5458-b356-3f6b521ef218","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2dbe7113-fbe3-5fd2-bca1-2846dd9a39c8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fbe34d96-9294-5a30-8de1-1bc1f631ce69","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"df527078-d479-5b6f-aff8-247af2cdd323","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1a8284ce-a2e5-59db-9d07-596f590c3ec3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9fe03c85-09a6-5232-8343-e77d91ad6145","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5bce13d-7bb2-5366-8bcc-28f538824ee4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f5e3b9df-860b-5c62-a358-a408038abc28","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"35a2dc51-a5b3-56bd-9a02-c420e08c1d0d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a74b3234-f02a-574d-8e07-00bdfc53cf94","slug":"mechanism-of-action","fullItemName":"Mechanism of action","depth":3,"htmlHeader":"<!-- begin field 280b75dd-15f9-4c13-a6fe-ed0e75d93642 --><h3>What is the mechanism of action of statins?</h3><!-- end field 280b75dd-15f9-4c13-a6fe-ed0e75d93642 -->","summary":"","htmlStringContent":"<!-- begin item af95bcde-9133-465c-9cd0-c978ad143dbf --><!-- begin field 543704ac-b0ae-40f5-9cb5-5bad52a4a123 --><ul><li>Statins inhibit 3-hydroxy-3-methylglutaryl co-enzyme A (HMG CoA) reductase, an enzyme involved in cholesterol synthesis. Inhibition of HMG CoA reductase reduces low density lipoprotein cholesterol (LDL-C) levels by slowing down the production of cholesterol in the liver and increasing the liver's ability to remove the LDL-C already in the blood [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Joint Formulary Committee, 2019</a>]. </li></ul><!-- end field 543704ac-b0ae-40f5-9cb5-5bad52a4a123 --><!-- end item af95bcde-9133-465c-9cd0-c978ad143dbf -->","subChapters":[]},{"id":"65e1a60f-e26c-504b-87e7-0fda0b71b3e6","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 3b700de2-adbb-496d-9766-27510aebb898 --><h3>Cautions and contraindications</h3><!-- end field 3b700de2-adbb-496d-9766-27510aebb898 -->","summary":"","htmlStringContent":"<!-- begin item 7377805a-1370-43a0-b8eb-e44880c986f9 --><!-- begin field 3a76eb76-5a4c-4a0a-a655-7ea8ea4f8433 --><ul><li><strong>Do not prescribe atorvastatin to:</strong><ul><li>People with active liver disease, or unexplained persistent elevations of transaminases that are three or more times the upper limit of normal.</li><li>Women who are pregnant or breastfeeding.</li><li>Women of child-bearing potential not using appropriate contraception.</li></ul></li><li><strong>Prescribe atorvastatin with caution to people:</strong><ul><li>With pre-disposing factors for rhabdomyolysis, including:<ul><li>Renal impairment, hypothyroidism, personal or familial history of hereditary muscular disorders, previous history of unexplained muscle pain (whether associated or not with previous lipid-regulating drugs), a history of liver disease or where substantial quantities of alcohol are consumed, in elderly (aged over 70 years), taking other medicines that interact and may cause plasma levels to increase.</li></ul></li><li>With a history of haemorrhagic stroke.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 3a76eb76-5a4c-4a0a-a655-7ea8ea4f8433 --><!-- end item 7377805a-1370-43a0-b8eb-e44880c986f9 -->","subChapters":[]},{"id":"ce8d7dc2-e2f3-554c-97c8-36a81053d771","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e20bd1a1-d2e7-42f7-b533-5b52cc85fd87 --><h3>Drug interactions</h3><!-- end field e20bd1a1-d2e7-42f7-b533-5b52cc85fd87 -->","summary":"","htmlStringContent":"<!-- begin item 410265d8-85d1-440c-98c1-7c037d70388c --><!-- begin field e086fe78-f8ba-4085-9dce-2479377512df --><ul><li><strong>Amiodarone</strong> — the incidence of myopathy may be increased if amiodarone is taken concurrently with statins. Monitor for adverse effects, and advise people to report any unexplained muscle aches, tenderness, cramps, stiffness or weakness.<ul><li>Consider giving a lower maximum dose of atorvastatin.</li><li>Do not exceed 20 mg simvastatin daily. </li></ul></li><li><strong>Ciclosporin</strong> — exposure to atorvastatin is increased. Do not exceed 10 mg of atorvastatin daily. <ul><li>Concurrent use with simvastatin is contraindicated. </li></ul></li><li><strong>Danazol </strong>— rhabdomyolysis has been reported with concurrent use. Advise people taking atorvastatin to report any unexplained muscle pain, tenderness or weakness.<ul><li>Concurrent use with simvastatin is contraindicated, but if necessary give the lowest possible dose and monitor closely. Advise people to report any unexplained muscle pain, tenderness or weakness.</li></ul></li><li><strong>Amlodipine, diltiazem, verapamil</strong> — concurrent use may increase statin levels. Consider reducing the statin dose, or starting with the lowest possible dose. Monitor concurrent use and advise people to report any unexplained muscle pain, tenderness or weakness.<ul><li>Do not exceed 20 mg simvastatin daily. </li></ul></li><li><strong>Erythromycin, telithromycin, clarithromycin </strong>— concurrent use may increase statin levels, and rhabdomyolysis has been reported. Avoid co-administration if possible (consider temporary cessation of atorvastatin if antibiotic treatment is short term). If this is not possible, consider using lower starting and maximum doses of atorvastatin and appropriate clinical monitoring of the person.<ul><li>Concurrent use with simvastatin is contraindicated. </li></ul></li><li><strong>Ezetimibe </strong>— risk of rhabdomyolysis may be increased. Advise people to report any unexplained muscle pain, tenderness or weakness.</li><li><strong>Fibrates </strong>— increased risk of rhabdomyolysis if taken concurrently with atorvastatin. If concurrent administration is necessary, reduce the starting dose of atorvastatin, and reduce the maximum dose of the fibrate.<ul><li>Concurrent use of gemfibrozil with simvastatin is contraindicated. </li></ul></li><li><strong>Grapefruit juice</strong> — may increase the plasma concentrations of atorvastatin and simvastatin.<ul><li>Advise against intake of large quantities (more than 1.2 L) of grapefruit juice with atorvastatin. Smaller amounts and separating administration by 12 hours reduces this effect.</li><li>Advise against intake of grapefruit juice with simvastatin.</li></ul></li><li><strong>HIV protease inhibitors</strong> (for example, ritonavir) — if concurrent use is unavoidable, give the lowest possible atorvastatin dose and monitor for statin adverse effects.<ul><li>Concurrent use of simvastatin and HIV protease inhibitors is contraindicated.</li><li>Telaprevir — concurrent use is contraindicated with atorvastatin.</li><li>Tipranavir — do not exceed 10 mg of atorvastatin daily. </li><li>Sofosbuvir/velptasvir/voxilaprevir — concurrent use with rosuvastatin is contraindicated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2020a</a>].</li></ul></li><li><strong>Azole antifungals</strong>  <ul><li><strong>Ketoconazole, voriconazole, itraconazole</strong> — concurrent use with simvastatin is contraindicated. Temporarily withhold atorvastatin or, if necessary, give the lowest possible dose. Advise people to report any unexplained muscle pains or weakness.</li><li><strong>Posaconazole</strong> — concurrent use with atorvastatin or simvastatin is contraindicated. </li><li><strong>Fluconazole</strong> — levels of statin may be increased. Give the lowest possible dose of atorvastatin and advise people to report any unexplained muscle pain, tenderness or weakness.</li></ul></li><li><strong>Oral fusidic acid</strong> — increased risk of myopathy including rhabdomyolysis. Avoid concurrent administration. <ul><li>If fusidic acid is essential, stop treatment with the statin and resume 7 days after the last dose of fusidic acid. Advise the person to seek medical advice immediately if they experience any symptoms of muscle weakness, pain, or tenderness.</li></ul></li><li><strong>Ticagrelor </strong>— levels of simvastatin may be slightly increased. If both drugs are given concurrently, advise people to report any unexplained muscle pain, tenderness, or weakness. Use a maximum simvastatin dose of 40 mg daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Preston, 2020</a>]. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field e086fe78-f8ba-4085-9dce-2479377512df --><!-- end item 410265d8-85d1-440c-98c1-7c037d70388c -->","subChapters":[]},{"id":"e779a537-2223-59cf-acf1-cf88e623d540","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3d4d039d-ef95-4a91-8c36-7a89d66bdca9 --><h3>Adverse effects</h3><!-- end field 3d4d039d-ef95-4a91-8c36-7a89d66bdca9 -->","summary":"","htmlStringContent":"<!-- begin item 26b499b7-00c8-42b0-870c-d2f87762d978 --><!-- begin field 721e4953-ea69-4b87-b773-6308e402b242 --><ul><li><strong>Gastrointestinal</strong> — constipation, flatulence, dyspepsia, nausea, and diarrhoea.</li><li><strong>Infections </strong>— nasopharyngitis (common).</li><li><strong>Metabolism and nutrition</strong> — hyperglycaemia (common). Hypoglycaemia, weight gain, anorexia (uncommon).</li><li><strong>Musculoskeletal and connective tissue</strong> — myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, and back pain (common). Neck pain, muscle fatigue (uncommon).<ul><li><strong>Rarely</strong>: myopathy and rhabdomyolysis (incidences of 1.6 cases per 100,000 person years and 5 cases per 100,000 person years, respectively), muscle rupture, immune-mediated necrotizing myopathy (IMNM) during or after treatment with some statins. IMNM is clinically characterized by persistent proximal muscle weakness and elevated serum creatine kinase, which persist even when statin treatment is discontinued.</li></ul></li><li><strong>Nervous system</strong> — headache (common), dizziness, paraesthesia, hypoesthesia, dysgeusia, amnesia (uncommon).<ul><li><strong>Rarely</strong>: peripheral neuropathy.</li></ul></li><li><strong>Psychiatric </strong>— insomnia, nightmares (uncommon).</li><li><strong>Respiratory</strong> — pharyngolaryngeal pain, epistaxis (common).<ul><li><strong>Rarely</strong>: interstitial lung disease — advise people to seek medical attention if they develop symptoms such as dyspnoea, cough, and weight loss.</li></ul></li><li><strong>Skin and subcutaneous tissue</strong> — urticaria, skin rash, pruritus, alopecia (uncommon).<ul><li><strong>Rarely: </strong>angioneurotic oedema, dermatitis bullous including erythema multiforme, lichenoid drug eruptions, Stevens-Johnson syndrome and toxic epidermal necrolysis.</li></ul></li><li><strong>Other rare or very rare adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Cholestasis, hepatic failure.</li><li>Depression.</li><li>Gynaecomastia.</li><li>Hearing loss.</li><li>Sexual dysfunction.</li><li>Visual disturbances (including blurred vision).</li><li>Lupus-like syndrome has been reported as a rare adverse effect with rosuvastatin.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 721e4953-ea69-4b87-b773-6308e402b242 --><!-- end item 26b499b7-00c8-42b0-870c-d2f87762d978 -->","subChapters":[]},{"id":"d24a0a88-acbe-59f0-81ca-b6e9450d3685","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 13d2f9f9-5e73-4537-8271-b3201470bef1 --><h3>Monitoring</h3><!-- end field 13d2f9f9-5e73-4537-8271-b3201470bef1 -->","summary":"","htmlStringContent":"<!-- begin item 91572d90-6b37-42f4-9e16-75a3a70156e4 --><!-- begin field 25c5b323-2bc8-4c05-9c9d-3a07429741eb --><ul><li><strong>Before initiating atorvastatin, </strong><strong>measure:</strong><ul><li>HbA1C or fasting blood glucose concentration in people at high risk of diabetes mellitus.</li><li>Liver function.</li><li>Full lipid profile (non-fasting), including total cholesterol, HDL-C and non-HDL-C and triglyceride concentrations.</li><li>Creatine kinase (CK) level in the following situations:<ul><li>Renal impairment, hypothyroidism, personal or familial history of hereditary muscular disorders, previous history of unexplained muscle pain (whether associated or not with previous lipid-regulating drugs), a history of liver disease or where substantial quantities of alcohol are consumed, in elderly (aged over 70 years), interactions with other medicines where plasma levels may be increased.</li></ul></li><li>Thyroid stimulating hormone levels.</li><li>Renal function. </li></ul></li><li><strong>After initiating atorvastatin:</strong><ul><li>Repeat liver function tests (LFTs) within 3 months of starting treatment, and again at 12 months, and at any other time if signs or symptoms suggest hepatotoxicity.</li><li>Check CK if unexplained muscle symptoms (such as pain, tenderness, or weakness) develop.</li><li>HbA1C or fasting blood-glucose concentration — repeat after 3 months in people at high risk of diabetes mellitus.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 25c5b323-2bc8-4c05-9c9d-3a07429741eb --><!-- end item 91572d90-6b37-42f4-9e16-75a3a70156e4 -->","subChapters":[]},{"id":"4f5f0054-2c4a-5a46-acc7-5878846e8ab1","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field c65093cb-3093-4095-94e8-a75b006f9b6c --><h3>What advice should I give to a person taking a statin?</h3><!-- end field c65093cb-3093-4095-94e8-a75b006f9b6c -->","summary":"","htmlStringContent":"<!-- begin item 9902c099-04b7-4ff5-b77d-a75b006f9bae --><!-- begin field e1b531ff-3cc8-42de-a946-a75b006f9b6c --><ul><li>Emphasize the importance of adherence to treatment (as well as compliance with lifestyle and dietary advice).</li><li>Advise the person:<ul><li>To seek medical advice if they develop <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/#adverse-effects\">adverse effects</a> such as:<ul><li>Unexplained muscle symptoms (pain, tenderness, or weakness).</li><li>Presenting features of interstitial lung disease such as dyspnoea, non-productive cough, and deterioration in general health (for example fatigue, weight loss, and fever).</li></ul></li><li>That some foods (for example grapefruit juice) and supplements (for example St John's wort) may <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/#drug-interactions\">interact</a> with statins. They should seek advice from their GP or pharmacist when starting other drugs or supplements.</li><li>To remember to restart the statin if stopped because of <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/#drug-interactions\">drug interactions</a> (for example with a macrolide antibiotic prescribed for an acute infection) or to treat intercurrent illnesses.</li><li>That atorvastatin can be taken at any time of the day.<ul><li>Simvastatin, pravastatin, and fluvastatin should be taken only in the evening.</li></ul></li></ul></li><li>Advise women of childbearing potential on the need for appropriate contraception due to the potential teratogenic risk of statins. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for information on choosing a suitable method of contraception.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>] </p><!-- end field e1b531ff-3cc8-42de-a946-a75b006f9b6c --><!-- end item 9902c099-04b7-4ff5-b77d-a75b006f9bae -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}